Business
Operational update on various investments
Operational update on various investments.
About this update from Truetide Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4527N\n Braveheart Investment Group plc\n 30 September 2021\n \n \n \n \n The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n \n 30 September 2021\n \n \n Braveheart Investment Group plc\n \n \n (\"Braveheart\" or the \"Group\")\n \n \n Operational update on various investments\n \n \n Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on two of the companies within the Group's investment portfolio. \n \n \n \n \n \n PhaseFocus Holdings\n \n \n \n \n \n PhaseFocus continues to make positive progress, achieving its highest ever sales in H1 2021. In order to meet the increased demand for Livecyte™ systems, the company has opened a new manufacturing facility in Nottingham. \n \n \n \n \n \n The company's distributors, Nakayama in Japan and Sinsi Technology in China, are now able to make onsite demonstrations of Livecyte™ to a strong pipeline of prospective buyers. CELLINK AB, recently renamed BICO Group AB, PhaseFocus's EU and US distribution partner, also has a strong pipeline and a series of Livecyte™ demonstrations is planned for those territories. \n \n \n \n \n \n Braveheart is pleased to see the growth in sales of PhaseFocus's market leading Livecyte™ instruments to leading cell biology research institutions across the globe. The Directors believe the company has a strong future and Braveheart is working to seek an exit in the next 12 months, which, if achieved, could be at a valuation considerably in excess of the carrying value in Braveheart's accounts.\n \n \n \n \n \n \n \n \n Paraytec\n \n \n \n \n \n \n Paraytec's \n \n \n Platform Technology \n \n \n \n Paraytec has continued to refine the platform technology that underpins its proposed fast, sensitive COVID-19 test. The platform technology (product reference \"CX300\") comprises a low-cost instrument that utilises intense fluorescent light to detect small specific viruses or cells in a biological sample. The biological sample is presented to the instrument via a disposable cartridge conta...